Norethindrone Acetate in the Medical Management of Adenomyosis

Ozgul Muneyyirci-Delale, Ozgul Muneyyirci‐Delale, Ashadeep Chandrareddy, Siddhi Mankame, N. Osei-Tutu, Nanna Osei-Tutu, Hans von Gizycki
Pharmaceuticals (Basel, Switzerland) · 2012 · vol. 5(10) , pp. 1120–1127 · doi:10.3390/ph5101120 · PMID:24281260 · W1972290279
article OA: gold CC0 ⤵ 21 in-corpus citations
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This study evaluated norethindrone acetate in 28 premenopausal women with adenomyosis and found significant improvement in dysmenorrhea and bleeding scores, suggesting it as an effective, inexpensive medical alternative to surgery.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The role of norethindrone acetate (NA) in the management of adenomyosis was evaluated with a retrospective chart review of 28 premenopausal women between 27-49 years of age presenting with moderate to severe pelvic pain and bleeding. Bleeding and dysmenorrhea scores were analyzed using paired T-tests. There was significant improvement of both dysmenorrhea and bleeding after treatment. Age showed no correlation with dysmenorrhea or bleeding. Low dose NA could be considered an effective, well-tolerated and inexpensive medical alternative to surgery for treating symptomatic adenomyosis. Large multicentric studies may help validate our findings.

My notes (saved in your browser only)

Condition tags

adenomyosisdysmenorrhea

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (37)

Cited by (21)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:16:23.388809+00:00
License: CC0 · commercial use OK